These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16115187)

  • 1. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Expert Opin Pharmacother; 2005 Feb; 6(2):319-28. PubMed ID: 15757427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lanthanum carbonate.
    Freemont AJ
    Drugs Today (Barc); 2006 Dec; 42(12):759-70. PubMed ID: 17285149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorus management in end-stage renal disease.
    Finn WF
    Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum carbonate: a new phosphate binder.
    Behets GJ; Verberckmoes SC; D'Haese PC; De Broe ME
    Curr Opin Nephrol Hypertens; 2004 Jul; 13(4):403-9. PubMed ID: 15199290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
    Cizman B
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for hyperphosphatemia.
    Bellinghieri G; Santoro D; Savica V
    Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanthanum carbonate--a first line phosphate binder?
    de Freitas D; Donne RL; Hutchison AJ
    Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
    Zhou T; Li H; Xie W; Lin Z
    Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R; Zhang P; Smyth M; Pratt R
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.